Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Mantle Cell Lymphoma
Related studies linked through entity extraction aliases.
First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies
- Status
- RECRUITING
- Phase
- PHASE1
Zanubrutinib-based Induction and Maintenance Therapy in Young and Fit Patients With Untreated Mantle Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2 Maintenance (U2-CHOP-U2) in Previously Untreated Mantle Cell Lymphoma (MCL)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)
- Status
- WITHDRAWN
- Phase
- PHASE2
Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT
- Status
- COMPLETED
- Phase
- NA
Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance with Zanubrutinib for Newly-Diagnosed MCL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
The Role of 18F-FDG-PET for Staging and Prognostication
- Status
- COMPLETED
- Phase
- N/A
Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole
- Status
- COMPLETED
- Phase
- PHASE1
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1
Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Atrial Fibrillation in Patients Receiving Ibrutinib
- Status
- UNKNOWN
- Phase
- N/A
Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2